Phase I/II trial vorinostat in children with relapsed malignancies: interim analysis report
O Witt, J Burhenne, R Witt, T Milde, C van Tilburg, A Seitz, JP Schenk, A Eisenmenger, U Abel, I Karapanagiotou-Schenkel · Klinische Pädiatrie · 2014 · Heft 12
Bibliografische Angaben
Zusammenfassung
Introduction: Histone deacetylases (HDACs) are key enzymes controlling epigenetic and cytoplasmatic signalling pathways involved in apoptosis, differentiation, cell cycle control and drug resistance. Our group has previously shown that single members of the HDAC family 1 – 11harbor important functions in pediatric pre-clinical neuronal cancer models and are highly expressed in a pediatrictumor samples. In this multi-center phase I/II trial, pediatric patients with relapsed solid tumors, lymphoma or leukemias are treated with the HDAC inhibitor vorinostat. Methods: Children 3 – 18 years old with relapsed malignan…
